Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAIA Biotechnology Inc.

2.06
+0.15007.85%
Post-market: 2.100.0400+1.94%19:57 EDT
Volume:426.98K
Turnover:875.44K
Market Cap:60.95M
PE:-1.97
High:2.18
Open:1.85
Low:1.85
Close:1.91
Loading ...

MAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC study

TIPRANKS
·
26 Feb

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Business Wire
·
26 Feb

Maia Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

THOMSON REUTERS
·
25 Feb

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Business Wire
·
25 Feb

Amex Halt News Pending Lst 1.845100

THOMSON REUTERS
·
19 Feb

MAIA Biotechnology to sell 1.81M shares at $1.50 in private placement

TIPRANKS
·
19 Feb

Maia Biotechnology : to Use Proceeds Received From Private Placement to Fund Starting Cost for Part C of Phase Ii Trial Thio -101

THOMSON REUTERS
·
19 Feb

Maia Biotechnology Announces Private Placement of $2,715,000

THOMSON REUTERS
·
19 Feb

MAIA Biotechnology Announces Private Placement of $2,715,000

Business Wire
·
19 Feb

Maia Biotechnology Inc trading halted, news pending

TIPRANKS
·
19 Feb

MAIA Biotechnology Updates Executive Compensation Packages

TIPRANKS
·
07 Feb

Noble Financial Keeps Their Buy Rating on MAIA Biotechnology, Inc. (MAIA)

TIPRANKS
·
05 Feb

MAIA Biotechnology Reports Promising Phase 2 Trial Results

TIPRANKS
·
05 Feb

BUZZ-MAIA Biotechnology rises on lung cancer drug trial data

Reuters
·
05 Feb

MAIA Biotechnology announces updated data from THIO-101 trial

TIPRANKS
·
04 Feb

Maia Biotechnology Inc - Sees Opportunity for Accelerated FDA Approval of Thio

THOMSON REUTERS
·
04 Feb

Maia Biotechnology Announces Positive Efficacy Updates for Phase 2 Thio-101 Trial in Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
04 Feb

Maia Biotechnology Inc - Third Line Data Shows Median Overall Survival of 16.9 Months

THOMSON REUTERS
·
04 Feb

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Business Wire
·
04 Feb

MAIA Biotechnology to Present at Biotech Showcase 2025

Business Wire
·
10 Jan